@article{article_972097, title={Stevens-Johnson Syndrome Due to Cefepime Usage in A Leukemia Patient: A Case Report}, journal={Eskisehir Medical Journal}, volume={2}, pages={135–138}, year={2021}, DOI={10.48176/esmj.2021.30}, author={Okay Özgeyik, Müfide and Aybı, Ozge and Goker, Hakan}, keywords={Stevens-Johnson Sendromu, Lösemi, Sefepim}, abstract={Introduction: Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are severe mucocutaneous reactions, triggered by medications. Herein, we first reported a relapse acute myeloid leukemia (AML) patient who developed SJS/TEN syndrome after cefepime (β-lactam antibiotic) use for neutropenic fever. Case report: A 50-year-old male patient with AML had 25% blast rate at bone marrow biopsy in the twelve months after stem cell transplantation. Due to neutropenic fever, cefepime was started. After one day, ceftazidime was started because of some urticaria like lesions. Desquamation of the body was seen 2 days after ceftazidime. Bullous erythema multiforme/SJS/TEN was considered in the differential diagnosis. Cyclosporine 4 mg/kg per day was started. There was an alleviation in the lesions.
Conclusion: Susceptibility to SJS/TEN has somewhat increased hematological malignancies. Clinicians should be aware of any rashes occurring in the body after any medication, in these patients.}, number={2}, publisher={Eskişehir Şehir Hastanesi}